Prostate Cancer Therapeutics: A Global Strategic Business Report
San Jose, California (PRWEB) April 6, 2009
Growth in prostate cancer therapies can be attributed to the increase in number of prostate cancer incidences in men aged more than 60 years. Given the longevity of an average individual, and the rapidly aging world population, the risk of prostate cancer stands tall. Statistics reveal that an estimated 1.4 million new invasive cancer cases diagnosed in the US alone in the year 2008. Invasive cancer carries a high risk of spreading to the bone if left untreated, thereby making timely intervention of crucial importance. The market for world prostate cancer therapeutics continues to gain traction as companies explore advancements and improvements in drug delivery techniques translating to greater market opportunity.
Several options exist for treating prostate cancer in its early development stage. Radiation therapy or surgery offer effective cure when the disease is diagnosed in initial stages. External Beam Radiation Therapy entails release of radioactive beams, either exclusively to the prostate gland (radiation only for prostate) or may cover the adjacent pelvic lymph glands besides the prostate gland (full pelvic radiation). In Brachytherapy or crevice insertions, the surgeon keeps tiny seeds or pallets of radioactive substance straight inside the prostate gland.
Hormonal therapies are the most effective type of treatment for patients suffering with advanced stage prostate cancer, and are generally prescribed only second to radiation therapies with locally advanced disease patients. Hormone therapy can control prostate cancer for a time span, usually many years. However, many prostate cancers eventually start growing and spread to other parts of the body even though treating with hormone therapy. Such cancers are termed as Hormone-Refractory Prostate Cancer (HRPC).
Targeted cancer therapy, which led to significant improvement in treatment outcomes, is gaining momentum in the cancer treatment market. At present, there are no targeted therapy drugs approved for prostate cancer treatment. However, researchers are optimistic about the promising results with Selective Endothelin A Receptor Antagonist called atrasentan.
Key players dominating the global prostate cancer therapeutics market include Abbott Laboratories, Æterna Zentaris Inc., ALZA Corporation, Amgen Inc., AstraZeneca PLC, Medimmune, LLC, Bristol-Myers Squibb Company, Cell Genesys Inc., Dendreon Corporation, EUSA Pharma, F. Hoffmann-La Roche Ltd., Genentech Inc., GlaxoSmithKline Plc, Immunomedics, Inc., Indevus Pharmaceuticals Inc., Novartis AG, OSI Pharmaceuticals, Inc., Paladin Labs Inc., Pfizer Inc., Sanofi-Aventis SA, Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited, among others.
The report titled "Prostate Cancer Therapeutics: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of industry overview, new drug approvals and trials, product overview, key market trends, product introductions/innovations, profiles of major players, and recent industry activity. The report analyzes market data and provides analytics in value sales for Global Prostate Cancer Therapeutics market, covering major regional markets such as United States, Europe, and Rest of World.
For more details about this research report, please visit
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com